Clinical trials: sponsored by Zhejiang Cancer Hospital
Breast Cancer
Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy
Capecitabine is recommended for adjuvant treatment of advanced or metastatic breast cancer and is particularly effective in patients with triple-negative breast cancer (TNBC).
- Trial name
- CALORIE (NCT03821454)
- Testing
- Capecitabine
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Cancer Pain
Individualized Pharmaceutical-care for Inpatients With Cancer Pain
The purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant inpatients
- Trial name
- NCT03455023
- Testing
- pharmaceutical care
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
Cancer Pain
Individualized Pharmaceutical-care in Outpatients With Cancer Pain
The purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant outpatients
- Trial name
- NCT03439904
- Testing
- Pharmaceutical care
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Febrile Neutropenia
Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer
This clinical study is a multiple center, registering and real-world conditional research. The breast cancer patients planning for chemotherapy evaluated with medium-high risk of febrile neutropenia (FN) are recruited, receiving…
- Trial name
- NCT03618810
- Testing
- PEGCSF first level prophylactic use, PEGCSF second level prophylactic use
- Volunteers
- 2,000 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer
Some studies have demonstrated the efficacy of Abraxane in treating breast cancer in both adjuvant and metastatic settings. Few data is available on Abraxane in neoadjuvant treatment for breast cancer.
- Trial name
- NCT03647514
- Testing
- Abraxane, Xeloda
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer, Breast Diseases
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
This study will look at effects the combination of palbociclib and dose-dense neoadjuvant chemotherapy may have on triple negative breast cancer tumours which have not yet been treated.
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms
- Trial name
- PECP (NCT03756090)
- Testing
- Palbociclib, Epirubicin, Cyclophosphamide
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer
Some studies have demonstrated the efficacy of Abraxane in treating breast cancer in both adjuvant and metastatic settings. Few data is available on Abraxane in neoadjuvant treatment for breast cancer.
- Trial name
- NCT03647280
- Testing
- Abraxane, Epirubicin
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Malignant Neoplasm of Nasopharynx
A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients
The chemo-radiotherapy for the local advanced nasopharyngeal carcinoma patients will induce the mucosal ulcer and damage salivary glands. Consequently, it can disturb the nutrition conditions and clinical outcomes of patients.
- Trial name
- NCT02948699
- Testing
- Nutrison
- Where
- 2 sites in China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Head and Neck Neoplasms
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
This prospective randomized controlled clinical Trial will be performed in patients with locally advanced squamous cell carcinoma of the head and neck.
- Trial name
- NCT03678649
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma, PET/MR
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03657017
- Testing
- PET/MR
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy
Radiation induced oral mucositis which may result in reduced quality of life is commonly seen during radiotherapy, especially combined with chemotherapy. This study is a prospective, single center, and exploratory study.
- Trial name
- NCT03647527
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients
Tomotherapy is a new radiation planning and delivery technology which may allow for delivery of higher radiation doses with less damage to normal tissues.
- Trial name
- NCT03588403
- Testing
- TOMO, IMRT
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhejiang Cancer Hospital
Effect of Drugs, Safety Issues
Remifemin Preventing the Climacteric Symptoms in Breast Cancer
LHRH-a is an important hormone treatment in breast cancer especially in high-risk hormone receptor-positive patients or hormone receptor-negative but needing ovarian function protecting.
- Trial name
- NCT03339882
- Testing
- Remifemin
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients
This is a prospective, non-randomized phase III study observing the cognitive function changes with conformal hippocampus avoidance during intensity modulated radiotherapy for T4 nasopharyngeal carcinoma patients.
- Trial name
- NCT03411954
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Neoadjuvant Therapy
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
The investigators designed this study to investigate the effect of aromatase inhibitors (AI) plus chemotherapy versus chemotherapy as neoadjuvant treatment in postmenopausal hormone receptor-positive breast cancer.
- Trial name
- ACCN (NCT02769104)
- Testing
- Letrozole (Aromatase Inhibitors), AC*4-T*4
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Cancer Hospital
Liver Cancer
DEB-TACE Treatment in 367 Liver Cancer Patients
Introduction:The drug-eluting beads transarterial chemoembolization (DEB-TACE) is introduced to better improve efficacy and reduce the systemic toxicity in liver cancer patients on account of its higher intratumoral…
- Trial name
- NCT03317483
- Volunteers
- 367 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD)and safety of Apatinib combined with S-1 as Second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT03276156
- Testing
- Apatinib plus S-1
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhejiang Cancer Hospital
Cervical Cancer Stage IVB
Chemotherapy Plus Radiation Therapy in Treating Patients With Primary Stage IVB Cervical Cancer
This is a prospective, single arm, phase II trail to assess the effect of primary lesion radiotherapy in the treatment of stage IVB cervical cancer on the basis of systemic chemotherapy.
- Trial name
- NCT03175848
- Testing
- Chemotherapy,radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Zhejiang Cancer Hospital
Stage III Non-small-Cell Lung Cancer
Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
Resistance of hypoxic tumor cells to radiation is a significant reason of failure in the local control of tumors, especially the squamous cell carcinomas.
- Trial name
- NCT01733589
- Testing
- Recombinant human endostatin, Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles, cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
To evaluate the efficacy and safety of apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who failed prior platinum based chemotherapy
- Trial name
- NCT03213587
- Testing
- Apatinib
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Zhejiang Cancer Hospital